You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

ATX-559 Targeted Therapy for Advanced HER2-/BRCA+ or dMMR/MSI-H Breast Cancer

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients with Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers

Purpose: To study the safety, best dose, and effects (good and bad) of ATX-559, an experimental DHX9 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a BRCA1/2 mutation, or breast cancer with a dMMR or MSI-H mutation. You must have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-559, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-559 is an experimental targeted therapy called a DHX9 inhibitor. Blocking DHX9 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) mutations include MLH1, MSH2, MSH6, and PMS.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06625515' target='_blank'>ClinicalTrials.gov</a> </li></ul>
1

ATX-559 Targeted Therapy for Advanced HER2-/BRCA+ or dMMR/MSI-H Breast Cancer

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients with Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers
Icon

Nearest Location:
1481 miles
NEXT Oncology
San Antonio, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06625515

Icon

Phase I

HELP GUIDE
HELP GUIDE